Review of Multiple Myeloma Genetics Including Effects on Prognosis, Response to Treatment, and Diagnostic Workup

Overview

Journal Life (Basel)

Specialty Biology

Date 2022 Jun 24

PMID 35743843

Authors

Julia Erin Wiedmeier-Nutor

Peter Leif Bergsagel

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma is a disorder of the monoclonal plasma cells and is the second most common hematologic malignancy. Despite improvements in survival with newer treatment regimens, multiple myeloma remains an incurable disease and most patients experience multiple relapses. Multiple myeloma disease initiation and progression are highly dependent on complex genetic aberrations. This review will summarize the current knowledge of these genetic aberrations, how they affect prognosis and the response to treatment, and review sensitive molecular techniques for multiple myeloma workup, with the ultimate goal of detecting myeloma progression early, allowing for timely treatment initiation.

Citing Articles

Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.

Veryaskina Y, Titov S, Skvortsova N, Kovynev I, Antonenko O, Demakov S Int J Mol Sci. 2025; 25(24.

PMID: 39769169 PMC: 11679576. DOI: 10.3390/ijms252413404.

The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.

Ram M, Fraser M, Vieira Dos Santos J, Tasakis R, Islam A, Abo-Donia J Pharmgenomics Pers Med. 2024; 17:573-609.

PMID: 39723112 PMC: 11669356. DOI: 10.2147/PGPM.S350238.

A comprehensive review of oncogenic Notch signaling in multiple myeloma.

Roosma J PeerJ. 2024; 12:e18485.

PMID: 39619207 PMC: 11608568. DOI: 10.7717/peerj.18485.

Chimeric Antigen Receptor T Cells for the Treatment of Multiple Myeloma.

Testa U, Pelosi E, Castelli G Mediterr J Hematol Infect Dis. 2024; 16(1):e2024077.

PMID: 39534712 PMC: 11556426. DOI: 10.4084/MJHID.2024.077.

An Unusual Increase in the CD38 Marker Observed in a Multiple Myeloma Patient With t(11;14) Translocation: A Case Report.

Rivera Troia F, Ocasio Villa F Cureus. 2024; 16(7):e63563.

PMID: 39087203 PMC: 11289740. DOI: 10.7759/cureus.63563.

References

Yellapantula V, Hultcrantz M, Rustad E, Wasserman E, Londono D, Cimera R . Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer J. 2019; 9(12):101. PMC: 6906304. DOI: 10.1038/s41408-019-0264-y. View

Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Harousseau J, Minvielle S . Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002; 99(6):2185-91. DOI: 10.1182/blood.v99.6.2185. View

Tschautscher M, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy M, Gertz M . Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. Am J Hematol. 2019; 94(7):751-756. DOI: 10.1002/ajh.25481. View

Weinhold N, Ashby C, Rasche L, Chavan S, Stein C, Stephens O . Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016; 128(13):1735-44. PMC: 5043128. DOI: 10.1182/blood-2016-06-723007. View

Dimopoulos M, Oriol A, Nahi H, San-Miguel J, Bahlis N, Usmani S . Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 375(14):1319-1331. DOI: 10.1056/NEJMoa1607751. View

Bergsagel P, Kuehl W . Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005; 23(26):6333-8. DOI: 10.1200/JCO.2005.05.021. View

Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford A . Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020; 38(21):2380-2389. PMC: 7367550. DOI: 10.1200/JCO.20.00437. View

Murray D, Puig N, Kristinsson S, Usmani S, Dispenzieri A, Bianchi G . Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021; 11(2):24. PMC: 7873248. DOI: 10.1038/s41408-021-00408-4. View

Martinez-Lopez J, Lahuerta J, Pepin F, Gonzalez M, Barrio S, Ayala R . Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014; 123(20):3073-9. PMC: 4023416. DOI: 10.1182/blood-2014-01-550020. View

10.

Barwick B, Gupta V, Vertino P, Boise L . Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Front Immunol. 2019; 10:1121. PMC: 6558388. DOI: 10.3389/fimmu.2019.01121. View

11.

Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F . Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132(6):587-597. PMC: 6097138. DOI: 10.1182/blood-2018-03-840132. View

12.

Rustad E, Yellapantula V, Leongamornlert D, Bolli N, Ledergor G, Nadeu F . Timing the initiation of multiple myeloma. Nat Commun. 2020; 11(1):1917. PMC: 7174344. DOI: 10.1038/s41467-020-15740-9. View

13.

Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G . Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2013; 28(3):675-9. PMC: 6140327. DOI: 10.1038/leu.2013.225. View

14.

Kalff A, Spencer A . The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012; 2:e89. PMC: 3461707. DOI: 10.1038/bcj.2012.37. View

15.

Bergsagel P, Kuehl W . Promiscuous Structural Variants Drive Myeloma Initiation and Progression. Blood Cancer Discov. 2021; 1(3):221-223. PMC: 8504774. DOI: 10.1158/2643-3230.BCD-20-0170. View

16.

Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F . A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2018; 33(1):159-170. PMC: 6326953. DOI: 10.1038/s41375-018-0196-8. View

17.

Kumar S, Kaufman J, Gasparetto C, Mikhael J, Vij R, Pegourie B . Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017; 130(22):2401-2409. DOI: 10.1182/blood-2017-06-788786. View

18.

Lohr J, Kim S, Gould J, Knoechel B, Drier Y, Cotton M . Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016; 8(363):363ra147. PMC: 5426804. DOI: 10.1126/scitranslmed.aac7037. View

19.

Chesi M, Bergsagel P, Shonukan O, Martelli M, Brents L, Chen T . Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998; 91(12):4457-63. View

20.

San Miguel J, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9):906-17. DOI: 10.1056/NEJMoa0801479. View